FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 315:785-790 September 25, 1986 Number 13 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We undertook a randomized, controlled trial to determine whether human surfactant administered endotracheally at birth to very premature infants (gestational age, 24 to 29 weeks) would prevent the respiratory distress syndrome or reduce its severity. Thirty-one treated infants (birth weight, 938 +/- 286 g) were compared in a blinded fashion with 29 control infants (birth weight, 964 +/- 174 g). The lecithin/sphingomyelin ratio was less than 2 in all infants, and phosphatidylglycerol was not present in amniotic fluid or tracheal fluids at birth, indicating a deficiency of surfactant in the lungs. The principal dependent variables were neonatal death, the incidence of bronchopulmonary dysplasia, and the infant's requirement for respiratory support (and its complications). The surfactant-treated group had significantly fewer deaths than the control group (16 percent vs. 52 percent, P less than 0.001), fewer cases of bronchopulmonary dysplasia (16 percent vs. 31 percent), and significantly fewer cases of pulmonary interstitial emphysema (P less than 0.001) and pneumothorax (P less than 0.02). Prophylactic treatment with human surfactant also substantially reduced the period of neonatal intensive care. We conclude that treatment with human surfactant offers promise for improving the survival of very premature infants with a surfactant deficiency and for reducing the pulmonary sequelae of the respiratory distress syndrome.

This article has been cited by other articles:

• Mulrooney, N., Champion, Z., Moss, T. J. M., Nitsos, I., Ikegami, M., Jobe, A. H. (2005). Surfactant and Physiologic Responses of Preterm Lambs to Continuous Positive Airway Pressure. Am. J. Respir. Crit. Care Med. 171: 488-493 [Abstract] [Full Text]  
• Cabana, M. D., Benson, J. E., Smith, A. E., Baggett, H. C., Northington, F. J. (2000). Delayed Presentation of Pulmonary Interstitial Emphysema. CLIN PEDIATR 39: 299-302  
• Bhuta, T., Ohlsson, A. (1998). Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch. Dis. Child. Fetal Neonatal Ed. 79: 26F-33 [Abstract] [Full Text]  
• Racine, A. D., Joyce, T. J., Li, W., Chiasson, M. A. (1998). Recent Declines in New York City Infant Mortality Rates. Pediatrics 101: 682-688 [Abstract] [Full Text]  
• Bloom, B. T., Kattwinkel, J., Hall, R. T., Delmore, P. M., Egan, E. A., Trout, J. R., Malloy, M. H., Brown, D. R., Holzman, I. R., Coghill, C. H., Carlo, W. A., Pramanik, A. K., McCaffree, M. A., Toubas, P. L., Laudert, S., Gratny, L. L., Weatherstone, K. B., Seguin, J. H., Willett, L. D., Gutcher, G. R., Mueller, D. H., Topper, William. H (1997). Comparison of Infasurf (Calf Lung Surfactant Extract) to Survanta (Beractant) in the Treatment and Prevention of Respiratory Distress Syndrome. Pediatrics 100: 31-38 [Abstract] [Full Text]  
• Jobe, A. H. (1993). Pulmonary Surfactant Therapy. NEJM 328: 861-868 [Full Text]  
• Berry, D. D. (1991). Neonatology in the 1990's: Surfactant Replacement Therapy Becomes a Reality. CLIN PEDIATR 30: 167-172 [Abstract]